Shanghai, China, 17 January 2024 – NK CellTech Co., Ltd. (NK CellTech), a leading biotech company focused on the development of NK cellular therapies, is pleased to announce that the FDA has granted clearance for the clinical trial of NK010, the non-genetically modified natural killer cells. NK010 is the first non-genetically modified NK cells expended from allogeneic peripheral blood cell (PBMC) approved for clinical trial by the FDA from China.
The turn of spring and summer has brought us a string of good tidings and great joy. Mr. Zhigang Tian, a member of the Chinese Academy of Engineering, professor of the University of Science and Technology of China and chairman of NK CellTech......
Coming Soon
© Copyright by CSPC All rights reserved. ICP备字:沪ICP备2022013361号-1